Free Trial
NASDAQ:SMTI

Sanara MedTech Q3 2025 Earnings Report

Sanara MedTech logo
$28.26 -1.04 (-3.55%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$28.28 +0.01 (+0.05%)
As of 10/17/2025 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanara MedTech EPS Results

Actual EPS
N/A
Consensus EPS
-$0.24
Beat/Miss
N/A
One Year Ago EPS
N/A

Sanara MedTech Revenue Results

Actual Revenue
N/A
Expected Revenue
$26.63 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sanara MedTech Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Sanara MedTech Earnings Headlines

This Crypto Is Set to Explode in January
Curious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they understand the why, when, and how of crypto. Join our free 2‑day virtual summit and learn directly from the world’s top hedge fund managers who’ve built real portfolios and real wealth. You’ll walk away with actionable insights grounded in strategy—not hype. No FOMO. No fluff. Just clear steps to move from intrigued to informed about crypto.tc pixel
Sanara MedTech stock falls after CEO succession announcement
See More Sanara MedTech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sanara MedTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sanara MedTech and other key companies, straight to your email.

About Sanara MedTech

Sanara MedTech (NASDAQ:SMTI) is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies. The company offers a range of balloon-based dilation products, including multi­sinus dilation systems, as well as adjunctive instruments for tissue access and endoscopic visualization. Its ENT platform is complemented by specialized energy‐based ablation technologies and implantable devices designed to address complex nasal and ear disorders.

Following its establishment through a business combination in early 2022, Sanara MedTech continues to invest in clinical studies and product enhancements aimed at broadening indications and improving procedural efficiency. The company collaborates with leading physicians and academic centers to validate its technologies and expand training programs that support adoption by surgeons worldwide.

Headquartered in Irvine, California, Sanara MedTech serves markets across North America, Europe, Latin America and Asia Pacific through a combination of direct sales teams and distributor partnerships. Its leadership team comprises experienced executives and clinicians with backgrounds in medical device innovation, regulatory affairs and global commercialization. Looking forward, the company is positioned to leverage its established technology platforms to pursue growth opportunities in ENT and adjacent specialties.

View Sanara MedTech Profile

More Earnings Resources from MarketBeat